School of Chemical Sciences, University of Auckland, 23 Symonds Street, Auckland 1010, New Zealand.
Metallomics. 2022 Jul 25;14(7). doi: 10.1093/mtomcs/mfac043.
Metal complexes bind to a wide variety of biomolecules and the control of the reactivity is essential when designing anticancer metallodrugs with a specific mode of action in mind. In this study, we used the highly cytotoxic compound [RuII(cym)(8-HQ)Cl] (cym = η6-p-cymene, 8-HQ = 8-hydroxyquinoline), the more inert derivative RuII(cym)(8-HQ)(PTA) (PTA = 1,3,5-triaza-7-phosphaadamantane), and [RuII(cym)(PCA)Cl]Cl (PCA = pyridinecarbothioamide) as a complex with a different coordination environment about the Ru center and investigated their stability, interactions with proteins, and behavior in medium (αMEM) and human serum by capillary zone electrophoresis. The developed method was found to be robust and provides a quick and low-cost technique to monitor the interactions of such complexes with biomolecules. Each complex was found to behave very differently, emphasizing the importance of the choice of ligands and demonstrating the applicability of the developed method. Additionally, the human serum albumin binding site preference of [RuII(cym)(8-HQ)Cl] was investigated through displacement studies, revealing that the compound was able to bind to both sites I and site II, and the type of adducts formed with transferrin was determined by mass spectrometry.
金属配合物与广泛的生物分子结合,当设计具有特定作用模式的抗癌金属药物时,控制其反应性至关重要。在这项研究中,我们使用了高细胞毒性化合物 [RuII(cym)(8-HQ)Cl](cym = η6-p-cymene,8-HQ = 8-羟基喹啉)、惰性衍生物 RuII(cym)(8-HQ)(PTA)(PTA = 1,3,5-三氮杂-7-磷杂金刚烷)和 [RuII(cym)(PCA)Cl]Cl(PCA = 吡啶碳二硫酰胺),作为 Ru 中心配位环境不同的配合物,研究了它们在介质(αMEM)和人血清中的稳定性、与蛋白质的相互作用和行为。开发的方法被发现是稳健的,并提供了一种快速且低成本的技术来监测这些复合物与生物分子的相互作用。每个配合物的行为都非常不同,强调了配体选择的重要性,并证明了所开发方法的适用性。此外,通过置换研究研究了 [RuII(cym)(8-HQ)Cl] 与人血清白蛋白结合位点的偏好,表明该化合物能够结合位点 I 和位点 II,并且通过质谱确定了与转铁蛋白形成的加合物的类型。